As already stated above, TNF-α inhibitors, and especially infliximab, have an inferior safety profile in comparison with the newer cytokine inhibitors targeting IL-17 and IL-12/23, which is mainly due to a higher number of severe infections under TNF-α inhibitors (37, 38, 41) suggesting an impact on the immunologic surveillance of infectious diseases. Here, IL17A is linked to infectious disease.